Cyberonics sales hit by FDA rejection
This article was originally published in Clinica
Cyberonics' summer of discontent has taken its toll as the company recorded a $2m loss in net earnings for the second quarter, a contrast to last year's performance when the company netted a profit of nearly $4m during the same period. Second-quarter revenues also took a 13% fall from the previous year's level to $25.4m.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.